Summary: The Pharmacy Trap

The pill organizer sits on the kitchen counter, seven columns for seven days. Six prescriptions, none optional, all indefinite. Ninety percent of Americans over 65 take at least one prescription medication. Forty-two percent take five or more. And for decades, the system that prices those prescriptions has operated with a logic that has nothing to do with what a retired couple on a fixed income can afford.

The scale is staggering. Total U.S. prescription drug spending reached $600 billion in 2023. Medicare Part D spending nearly doubled in less than a decade. One in five seniors spent more than $1,000 out of pocket on prescriptions in the past year. More than a third of Medicare beneficiaries delayed or went without medical or prescription drug services because of cost. The people splitting pills or leaving prescriptions unfilled are not failing to follow medical advice. They are doing arithmetic.

The United States was, until recently, the only wealthy nation that did not negotiate the prices its public insurance programs pay for drugs. Medicare was explicitly prohibited from negotiating from the time Part D was created in 2003 until the Inflation Reduction Act changed the rules in 2022. The intermediaries that were supposed to negotiate on patients’ behalf, pharmacy benefit managers, were instead extracting billions. An FTC report found that the three largest PBMs marked up specialty generics by hundreds to thousands of percent above acquisition costs. The generic version of the cancer drug Gleevec carried a 5,232% markup.

The Inflation Reduction Act brought three changes that matter. Medicare can now negotiate prices directly with manufacturers for select high-expenditure drugs; the first ten, including Eliquis, Jardiance, and Januvia, took effect in January 2026 with reductions of 38% to 79% off list prices. A hard cap on annual Part D out-of-pocket spending ($2,000 in 2025, $2,100 in 2026) replaced the old coverage gap that left patients exposed to unlimited costs. And insulin is now capped at $35 per month for all Part D enrollees.

These are real improvements at real kitchen tables. They are also the beginning of a process, not the end. Ten drugs were negotiated in the first round. Medicare Part D covers thousands. A second round of fifteen drugs for 2027 includes Ozempic. A third round for 2028 will, for the first time, include physician-administered drugs under Part B.

Congress also passed PBM reforms in February 2026, delinking PBM compensation from drug prices and requiring full rebate pass-through to plans and patients. CMS has proposed two international reference pricing models (GLOBE for Part B, GUARD for Part D) that could reshape the pricing landscape further if finalized. The policy terrain is shifting faster than at any point in Medicare’s history.

The pill organizer on the counter is not going away. Review your Part D plan every year during Open Enrollment. Ask about generic alternatives and medication reviews. Check whether you qualify for Medicare Extra Help. Use the new monthly payment smoothing option if your costs cluster early in the year. The system that prices what goes into that organizer is finally beginning to change. Whether it changes fast enough is the question the next few years will answer.